Monomethyl triazeno imidazole carboxamide
CAS: 3413-72-7
Ref. 3D-FM26098
2mg | 250,00 € | ||
5mg | 351,00 € | ||
10mg | 468,00 € | ||
25mg | 729,00 € | ||
50mg | 1.214,00 € |
Información del producto
- MTIC3-methyl(triazenyl)imidazole-4-carboxamide5-(3-methyltriazen-1-yl)imidazole-4-carboxamide
- NSC 407347
- Imidazole-4(or 5)-carboxamide, 5(or 4)-(3-methyl-1-triazeno)-
- 1H-Imidazole-4-carboxamide, 5-(3-methyl-1-triazenyl)-
- 5-[2-(Methylimino)hydrazinyl]-1H-imidazole-4-carboxamide
- 1H-Imidazole-4-carboxamide, 5-[2-(methylimino)hydrazinyl]-
- Imidazole-4-carboxamide, 5-(3-methyl-1-triazeno)-
Monomethyl triazeno imidazole carboxamide (MTIC) is a drug that is used to treat cancer. It has been shown to inhibit the proliferation of tumor cells and induce apoptosis by inhibiting the expression of proteins, such as Bcl-2, which are involved in regulating mitochondrial membrane potential. MTIC has also been shown to inhibit protein synthesis and cell signaling pathways, such as the PI3K/Akt pathway. The use of MTIC for diagnosis purposes can be achieved using electrochemical impedance spectroscopy. A concentration-time curve can be obtained by incubating a biological sample with MTIC and measuring cell response using an impedance spectrophotometer. The clinical properties of MTIC include its ability to be administered orally or intravenously, have low toxicity, and inhibit the growth of tumor cells in vivo and in vitro.
Propiedades químicas
Consulta técnica sobre: 3D-FM26098 Monomethyl triazeno imidazole carboxamide
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.